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HpETE, hydroperoxy-eicosatetraenoic acid; 12-HETE, 12-hydroxy-eicosatetraenoic 
acid; 12-HpETE, 12-hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoic acid; 11-HETE, 
11-hydroxy-eicosatetraenoic acid; 15-HETE, 15-hydroxy-eicosatetraenoic acid; 15-
HpETE, 15-hydroperoxy-5Z,8Z,10Z,13E-eicosatetraenoic acid; 15-HpEDA, 15(S)-
hydroperoxy-11Z,13E-eicosadienoic acid; 13-HODE, 13(S)-hydroxy-9Z,11E-
octadecadienoic acid; 13-HpODE, 13(S)-hydroperoxy-9Z,11E-octadecadienoic acid; 
13-HOTrE, 13(S)-hydroxy-6Z,9Z,11E-octadecatrienoic acid; 13-HpOTrE, 13(S)-
hydroperoxy-6Z,9Z,11E-octadecatrienoic acid; 10-HpOTrE, 10(S)-hydroperoxy-
6Z,8E,12Z-octadecatrienoic acid.
Abstract:
Human platelet hALOX12 (hALOX12 or h12-LOX) has been implicated in a variety 
of human diseases. The present study investigates the active site of hALOX12 to 
more thoroughly understand how it positions the substrate and achieves nearly 
perfect regio- and stereo-specificities (i.e., 100 +/- 5% of the 12(S)-hydroperoxide 
product), utilizing site-directed mutagenesis. Specifically, we have determined that
Arg402 is not as important in substrate binding as previously seen for hALOX15, 
but that His596 may play a role in anchoring the carboxy terminal of the 
arachidonic acid during catalysis.  In addition, Phe414 creates a pi-stacking 
interaction with a double bond of arachidonic acid (), and Ala417/Val418 define 
the bottom of the cavity. However, the influence of Ala417/Val418 on the profile is 
markedly less for hALOX12 than that seen in hALOX15. Mutating these two 
residues to larger amino acids (Ala417Ile/Val418Met), only increased the 
generation of 15-HpETE by 24+/- 2%, but conversely smaller residues at these 
positions converted hALOX15 to almost 100% hALOX12 reactivity (JBC, 1996, 271, 
25412-25418). However, we were able to increase 15-HpETE to 46+/- 3% by 
restricting the width of the active site with the Ala417Ile/Val418Met/Ser594Thr 
mutation, indicating both depth and width of the active site are important. Finally, 
residue Leu407 is shown to play a critical role in positioning the substrate 
correctly, as seen by the increase of 15-HpETE to 21+/- 1% for the single 
Leu407Gly mutant. These results outline critical differences between the active 
site requirements of hALOX12 relative to hALOX15, and explain both their product 
specificity and inhibitory differences.

INTRODUCTION
Lipoxygenases (LOXs)1 are ubiquitous non-heme iron-containing 
dioxygenases that catalyze the oxidation of polyunsaturated fatty acids (PUFAs) 
with a cis,cis-1,4-pentadiene moeity.2, 3 Human LOXs are classified into three major
categories, 5-LOX,4 12-LOX,5 and 15-LOX6, designating which carbon in arachidonic 
acid (AA) is oxygenated to produce their respective hydroperoxyeicosatetraenoic 
acid (HpETE) product. The enzymes can be further classified based on the chirality 
of oxygen insertion, i.e., ‘R’ or ‘S’ LOXs. The HpETE products are subsequently 
reduced by glutathione peroxidase to form the hydroxyeicosatetraenoic acid 
(HETE).7-12 Accordingly, 12-lipoxygenase catalyzes the transformation of 
arachidonic acid into 12-HpETE. In humans, two 12-lipoxygenase isozymes are 
expressed, platelet-type 12(S)-Lipoxygenase (hALOX12 or h12-LOX) and epithelial-
type 12(R)-Lipoxygenase (hALOX12B or 12R-LOX).13, 14 hALOX12 makes the S-
product and is primarily expressed in platelets, whereas hALOX12B is primarily 
expressed in epithelial tissue and makes the R-product. hALOX12 has garnered the
majority of scientific attention because of its implication in a variety of human 
diseases, such as skin inflammation,15 certain cancers (i.e. breast,16, 17 pancreatic18 
and prostate19), blood coagulation,20 platelet activation21, 22 and diabetes.23 
One of the critical properties of LOXs is their ability to oxygenate fatty acids 
both regio- and stereo-specifically. The structural basis for this product specificity 
has been investigated extensively for human reticulocyte 15-lipoxygenase-1 
(hALOX15 or h15-LOX-1). Sigal and coworkers determined that F414 formed a pi-pi
stacking interaction with the ∆11-double bond of AA, while I417/M418 defined the 
bottom of the active site cavity for hALOX15, which positions the appropriate 
carbon for oxygenation.24, 25 This work was expanded by Kuhn and coworkers, who 
established that F353 in rabbit reticulocyte ALOX15 (rALOX15 or r15-LOX-1) also 
played a critical role in defining the overall size/shape of the active site, and thus 
the specificity for C-15 versus C-12 oxidation of AA (F352 in hALOX15).26, 27 These 
data led to the “triad” concept for rALOX15, wherein F353, I418 and I593, 
positioned in the deepest portion of the substrate-binding pocket, were critical for 
positional specificity (F352, I417 and I592 in hALOX15).28 Vogel et al. concluded 
that this hypothesis could explain the positional specificity of several mammalian 
ALOX15 enzymes, specifically those from rabbit, human, M. mulatta, P. pygmaeus 
and mouse.28 However, the specificity of hALOX12 was only partially explained by 
the triad hypothesis, and for human epithelial ALOX15B (hALOX15B or h15-LOX-2) 
and hALOX12B, the triad hypothesis did not apply.28 It has also been hypothesized 
that proper alignment of the substrates in LOX active sites additionally requires 
specific interactions with the carboxylate of the fatty acid. R402 has been 
proposed to play this role in hALOX15,25 but the effect of mutating this amino acid 
on enzyme kinetics could also be partially explained by de-stabilization of the 
tertiary structure.29 Overall, a three-point interaction mechanism is proposed for 
hALOX15 to align the substrate in the active site so that the iron abstracts a 
hydrogen from the appropriate bis-allylic carbon: (i) hydrophobic interaction of the 
methyl end of the substrate with the hydrophobic side chains of the bottom of the 
active site pocket, F352, I417 and I592; (ii) ionic interaction of the carboxylate end 
of the fatty acid with R402;25 and (iii) π- π interaction between the fatty acid double
bond (∆11) and F414.25 
The structural basis for product selectivity in hALOX12 has been less 
extensively studied, and previous mutagenesis studies indicate the positional 
specificity is more complicated than for human/rabbit ALOX15. For porcine 
leukocyte ALOX15 (pALOX15 or p12-LOX), a double mutation, V418I/V419M, was 
sufficient to produce 85% 15-HpETE, versus 10% for the wild-type enzyme.30 
However, pALOX15 is more closely related to hALOX15 than hALOX12. For 
hALOX12, the factors governing positional specificity are not as straightforward. In 
particular, hALOX12 generates insignificant quantities of 15-HpETE, and the double
mutant, A417I/V418M (I417/M418 for hALOX15 and V418/V419 for pALOX15) 
increased the 15-HpETE percentage to only 14%.28 K416 was also proposed to be a
specificity determinant but the triple mutant K416Q/A417I/V418M only increased 
15-HpETE to 20% of the total.31 The substitution of the remaining amino acid 
variants between positions 398-429 in hALOX12 to the corresponding hALOX15 
amino acids (T401V/Q406G/I408V/G411M-/K416Q/A417I/V418M) increased 15-
HpETE to 66%, however, the enzyme activity was reduced to 25% of the wt-
hALOX12 activity, indicating extensive structural changes.31 Other aspects of the 
three-point interaction hypothesis, including the positioning of the carboxylate 
(R402) and possible pi-pi interactions (F414), were not previously tested for 
hALOX12.  
In the current work, we expand our investigations of the size and shape of 
the active site of hALOX12, as well as probe the role of R402 and F414. This work 
refines the multi-point interaction properties between AA and hALOX12, and 
determine that the hALOX12-substrate interactions are similar but not analogous 
to the previously described interactions observed in hALOX15.
MATERIAL AND METHODS 
Chemicals. All the fatty acids used in this study were purchased from Nu-Chek 
Prep, Inc. (MN, USA). All other solvents and chemicals were of reagent grade or 
better and were used as purchased without further purification. 
Homology Model of hALOX12 and docking of arachidonic acid. A crystal 
structure of human ALOX12 is available in the Protein Data Bank (pdb id: 3d3l, 
resolution 2.6Å), however, this structure is not suitable for the present modeling 
due to several missing residues.  For instance, helix 11, located at the entrance of
the active site in rabbit ALOX15 and porcine ALOX15 structures, is missing in the 
hALOX12 structure.  Also, helix 2, positioned parallel to the helix 11 in rabbit 
ALOX15 and porcine ALOX15 structures, is re-oriented horizontally above the 
active site entrance in the hALOX12 structure (structural superposition is shown in 
Figure S1 of Supplementary Information).  Therefore, the active site is fully 
exposed to the solvent.  Further, the C-terminal residue, I663, whose carboxylate 
coordinates to the active site ferric ion, is missing in the hALOX12 structure.  
Finally, McGovern et. al. have shown that structure-based virtual screening 
calculations performed better if the structure had a ligand bound in the active 
site,32 but the hALOX12 structure does not contain a ligand in the active site.   
However, the structure of porcine leukocyte ALOX15, a close homolog of hALOX12,
(pdb is: 3rde, 66% sequence identity), contains a substrate-mimetic, inhibitor 
bound in the active site. In addition, its crystal structure resolution is 1.9Å, better 
than that of the hALOX12 structure.  Therefore, we decided to build a homology 
model of hALOX12 based on the porcine hALOX15 structure.  The homology model 
of hALOX12 (Uniprot accession P18054) was built using the software PRIME (v4.7, 
Schrödinger Inc).  During homology modeling we retained the metal ion (Fe3+), a 
hydroxide ion coordinated to the metal ion, and the co-crystallized ligand, 3-(4-
[(tridec-2-yn-1-yloxy) methyl]phenyl)propanoic acid, from the porcine ALOX15 
structure. The hALOX12 model was subsequently energy minimized using Protein 
Preparation Wizard (Schrödinger Inc).  During the protein preparation step, 
hydrogen atoms were optimized to make better hydrogen bonding interactions and
all heavy atoms were relaxed such that they did not move beyond 0.3 Å from their 
starting position.   After the protein preparation step, we deleted the co-
crystallized ligand from the template structure, but retained the metal (Fe3+) and 
hydroxide ion.  
The AA substrate and a C10-carbanion reaction intermediate were prepared 
using the Edit/Build panel (Maestro v11.1.012, Schrödinger Inc), and then energy 
minimized using LigPrep (v41012, Schrödinger Inc).  We set OPLS-2005 atom-type 
parameters for the reaction intermediate during LigPrep energy minimization.  We 
subsequently used Glide (v7.4, Schrödinger Inc) to dock both compounds using 
flexible ligand sampling and extra precision (XP) scoring function options.  Glide 
docking consisted of a grid preparation step and a docking step.  We used the 
centroid of the co-crystallized ligand from the template structure to define the 
binding site.  
Site-directed Mutagenesis.  Guided by the model of hALOX12 and the predicted
binding model of the arachidonic acid C10 carbanion reaction intermediate, we 
chose the following amino acid mutations to test their importance for substrate 
positioning: R402L, L407G, L407A, F414L, F414W, A417I, V418M, A417I/V418M, 
A417I/V418M/S594T and H596L. The numbering in the text refers to UniProt 
accession number P18054 for the hALOX12 sequence without 6XHis-tag and with 
the N-terminal methionine assigned as amino acid number one.  Online 
QuikChange Primer Design tool (http://www.genomics.agilent.com/ 
primerDesignProgram.jsp) from Agilent Technologies (CA, USA) was used to 
design the primers for all the mutants of hALOX12. The mutations were introduced 
using a QuikChange®II XL site-directed mutagenesis kit from Agilent Technologies 
using the provided protocol. The mutations were confirmed by sequencing the 
hALOX12 insert in the pFastBac1 shuttle vector (Eurofins Genomics, KY, USA).
Protein Expression and Purification. The expression and purification of 
hALOX12 and all mutant enzymes used in this study were performed as previously 
described.33 The wild-type hALOX12 (wt-hALOX12) enzyme and its mutants were 
expressed as fusion proteins with a 6-His tag on the N-terminus and were purified 
by affinity nickel-iminodiacetic acid agarose using a FPLC (Biorad). The entire 
purification process was performed at 4°C.  The purity of all proteins was greater 
than 90%, as determined by SDS-PAGE analysis and the oligomeric state similar to 
wt-hALOX12, as determined by SEC.
Determination of Iron Content using ICP-MS. The iron content of wt-hALOX12 
and all the mutant enzymes was determined on a Thermo Element XR inductively 
coupled plasma mass spectrometer (ICP-MS). Cobalt (EDTA) was used as an 
internal standard. Iron concentrations were compared with standardized iron 
solutions and all the Kinetic data were normalized to the iron content. Protein 
concentrations were determined by a Bradford assay, with bovine serum albumin 
(BSA) as protein standard.
Steady-state Kinetics. hALOX12 and all the mutant protein enzymatic rates 
were determined by following the formation of the conjugated diene product, 
12(S)-HpETE, ( = 27,000 M-1cm-1) at 234 nm with Perkin-Elmer Lambda 40 UV/Vis 
spectrophotometer. The reactions were done in triplicate and started by adding 
approximately 40 nM enzyme to a 2 mL reaction mixture containing 1 to 20 µM AA,
in 25 mM HEPES buffer (pH 8.00), at room temperature (23°C), with constant 
stirring. Triton X-100 (0.01% by wt) was added to reduce substrate inhibition, of 
which minimal inhibition was observed up to 20 µM AA. Kinetic data were obtained 
by recording initial enzymatic rates at each substrate concentration and then 
fitting them to the Michaelis-Menten equation using the KaleidaGraph (Synergy) 
program to determine kcat and kcat/ KM values.
LC/MS Analysis of Enzymatic Products. To determine the products formed, wt-
hALOX12 and the mutant enzymes were added to a solution of 25 mM HEPES 
buffer (pH 7.5) and 10 μM of a fatty acid substrate (arachidonic acid, 
docosahexaenoic acid, eicosadienoic acid, gamma linoleic acid, linoleic acid) for 10
minutes, in triplicate. The reactions were quenched with 1% glacial acetic acid and 
extracted three times with dichloromethane (DCM). The products were then 
reduced with trimethylphosphite and evaporated under a stream of N2 gas. The 
reaction products were reconstituted in methanol and analyzed via LC-MS/MS. 
Chromatographic separation was performed using a C18 Synergi (4μM) Hydro-RP 
80 Angstrom LC column (150 x 2mm). The injection volume was 20 μL. The 
chromatography system was coupled to a Thermo-Electron LTQ LC-MS/MS for mass
analysis. All analyses were performed in negative ionization mode at the normal 
resolution setting. The 2 mobile phases (A and B) consisted of water with 0.1% 
(v/v) formic acid and acetonitrile with 0.1% formic acid, respectively. The protocol 
ran 60% mobile phase A and 40% mobile phase B initially, then at 30 minutes 
decreased mobile phase A to 55% and increased mobile phase B to 45%, and 
finally gradually decreased the percentage of mobile phase A and increased the 
percentage of mobile phase B until it reached 25% mobile phase A and 75% mobile
phase B at 60 minutes. The flow rate was 200 μL/min. The products were ionized 
by electrospray ionization. MS2 was performed in a targeted manner with a mass 
of 319.5 (for HETE detection). Thermo PDA Plus UV detectors were used. Products 
were identified by matching retention times, fragmentation and UV spectra to 
known standards. 
RESULTS and DISCUSSION
Model of hALOX12 with substrate and reaction intermediate
To guide the design and interpretation of the mutagenesis studies, we 
created a homology model of hALOX12, and then used computational docking to 
predict the binding mode of arachidonic acid (substrate) and a carbanion reaction 
intermediate (an approximation of the arachidonyl radical).  The LOX reaction 
mechanism involves the abstraction of a hydrogen atom from the bisallylic 
methylene, thereby producing a free radical at the methylene carbon (i.e. C10).  
Unfortunately, the force-field used in molecular docking calculations does not 
support free radical atom-type.  Therefore, we modeled the lone-pair electron on 
C10 as a carbanion for docking purpose. Results using the intermediate were more
consistent with available experimental data, similar to earlier work by Hermann et 
 
Figure 1. Two representations of the predicted binding mode of the AA C-10 carbanion
intermediate in the hALOX12 wild-type enzyme active site.  The negatively charged
carbanion C10 is identified with a star (*).  H596 is predicted to form a hydrogen bond
to the carboxylate group of the fatty acid.  The AA carbanion intermediate is shown in
a ball-and-stick and surface representations.  The hydroxide ion is shown in a ball-and-
stick representation while the key residues that are mutated in this study are shown in
a stick representation.  Carbon atoms of AA and the protein are shown in grey and
green, respectively.  Iron is  depicted as an orange sphere.   Nitrogen, oxygen atom
hydrogen atoms are shown in blue, red and white colors, respectively.  
al., who showed that docking high-energy reaction intermediates of substrate 
molecules was better in identifying substrates than docking ground-state substrate
molecules alone in a large metabolite library docking study.34 An extra-precision 
(XP) docking score of -4.2 was obtained and its docking pose is shown in Figure 1.
The carbanion locks the substrate into a position consistent with the characterized 
enzyme mechanism, in which the ferric-hydroxide abstracts the hydrogen atom 
from C10, generating a pentadienyl radical.  Specifically, the carbanion on C10 is 
4.9 Å from the metal ion (Fe3+) and 3.0 Å to the hydrogen atom of the hydroxide 
ion. As expected, the hydrophobic C20 terminal methyl of AA binds deeply in the 
hydrophobic pocket created by F352, F414, V418, C559 and L589.  The distance 
between the carbanion intermediate and the side chains of residues that interact 
with the intermediate are given in the Supporting Information (Table S1).  The 
predicted docking score for AA was -2.3 and it bound outside the catalytic site.
Binding interactions with the carboxylate moiety of arachidonic acid
Previously, Gan et al. demonstrated that R402 in hALOX15 interacted with 
the carboxylate moiety of the fatty acid substrate, positioning the substrate in the 
active site relative to the catalytic iron for hydrogen atom abstraction.25 R402 is 
conserved in both hALOX15 and hALOX12 (R402), suggesting that it might play a 
similar role for fatty acid binding in hALOX12.  However, the model of hALOX12 
with the reaction intermediate predicts that the carboxylic acid of AA makes a 
hydrogen bonding interaction with H596 (Q595 in hALOX15) and not R402. We 
therefore mutated both R402 and H596 to test these competing hypotheses.  
To interrogate the role of R402, we replaced it with a nonpolar leucine to 
disrupt the proposed hydrogen bond interaction with the substrate. This hALOX12 
mutant, R402L, demonstrated only a 2-fold decrease in kcat/KM when compared to 
wt-hALOX12, 6.3  0.5 µM-1s-1 and 14  0.9 µM-1s-1, respectively (Table 1). There 
was also no significant change in the KM value of AA, which was 0.89  0.09 µM for 
R402L and 1.9  0.2 µM for wt-hALOX12. R402L therefore has an effect on 
catalysis, but it is not nearly as dramatic as that seen for hALOX15, where kcat/KM 
decreased by 136-fold with the analogous mutation. The R402L mutation also did 
not significantly impact the positional specificity of hALOX12, as both wt-hALOX12 
and R402L yielded approximately 100% 12-HETE (Table 1), in contrast to previous
results on hALOX15, which showed a larger change in product profile. Both the 
kinetic and specificity results suggest that R402 of hALOX12 does not interact with 
AA as significantly as it does in hALOX15. It should be noted that in Plexaura 
homomalla (black sea whip coral) 8R-LOX (cALOX8),35 they observe R182 directly 
interacting with the carboxylate of AA, but the R182L mutant only manifests a 2-
fold decrease in kcat/KM, similar to hALOX12. However, they also observe significant 
substrate inhibition with the R182L mutant, which we do not observe for the 
hALOX12 R402L mutant. Considering that cALOX8 only shares 30% sequence 
identity with hALOX12, it is difficult to compare these two LOX isozymes with 
respect to this mechanistic detail, but we still cannot completely rule out a 
substrate binding role for R402 in hALOX12 based on the cALOX8 result. 
hALOX12 also accepts docosahexaenoic acid (DHA) as a substrate, with 
similar reaction kinetics to that of AA (Table 1) and since DHA is 2 carbons longer 
than AA, it is possible DHA could interact with R402. We therefore tested if R402 
might coordinate the carboxylate of DHA, however, no significant change in the 
activity was observed with DHA between wt-hALOX12 and R402L, further 
supporting our hypothesis that R402 in hALOX12 does not interact with the 
carboxylate group of its fatty acid substrates significantly. A minor change was 
observed in the product distribution which also supports a minimal effect of R402 
on catalysis. It should be noted that the percent of 11-HDHA:14-HDHA is larger 
than reported previously with hALOX12 from E. coli.,36 which is possibly due to the 
fact that the current work expresses hALOX12 in SF9 cells. We are currently 
investigating this further.
To test the alternate hypothesis suggested by the computational model, 
H596 was replaced with a nonpolar leucine (H596L) to disrupt H-bonding with the 
substrate, but only a relatively small decrease in enzyme activity was observed. 
Kinetic characterization of H596L under steady-state conditions showed a 2-fold 
decrease in kcat/KM relative to wt-hALOX12, 6.3 ± 0.4 and 14  0.9, respectively, 
and 3-fold decrease in kcat (8.6  0.7 s-1) relative to wt-hALOX12 (28  0.9 s-1) 
(Table 1). However, more significant changes were observed in positional 
specificity, with H596L producing both 12-HETE and 15-HETE, in a ratio of ~3:1, 
along with a small amount of 11-HETE (5+/- 1%), while wt-hALOX12 produced 
100+/- 5% 12-HETE. We hypothesize that in H596L, the carboxylate group of AA 
now interacts with R402, which could explain the production of 15-HETE upon 
H596L mutation.  In order to test this hypothesis, we docked C13-carbanion 
intermediate of AA to hALOX12 with H596L mutation, and the carboxylate group 
can indeed hydrogen bond to R402, positioning the reactive carbon atom, C13, 5.0
Å away from the metal ion (please see supplemental information, Figure S2).  
These results suggest that H596 in wt-hALOX12 may contribute to properly 
positioning AA for catalysis, possibly through its interaction with the carboxylate 
moiety of AA.
π- π interactions of AA double bonds with aromatic amino acids of 
hALOX12
Based on their model of substrate binding in hALOX15, Gan et al. identified F414 as
an important substrate binding determinant,25 proposing that the ∆11-double bond 
of AA participated in a π- π interaction with the aromatic side chain. We mutated 
the corresponding amino acid in hALOX12, F414L, resulting in a 12-fold decrease in
the kcat/KM, and a 16-fold decrease in kcat (Table 2).  In contrast, F414W resulted in 
Substrate Arachidonic acid Docosahexaenoic acid
Enzymes wt-hALOX12 H596L R402L
wt-
hALOX12 R402L
KM (µM) 1.9 ± 0.2 1.3 ± 0.4 0.89 ±0.09 0.59 ± 0.1 1.5 ± 0.5
Kcat (s-1) 28 ± 0.9 8.6  0.7 5.6 ± 0.1 4.5 ± 0.1 5.6 ± 0.5
Kcat/KM (µM)-1s-
1 14 ± 0.9 6.3 ± 0.4 6.3 ± 0.5 7.6 ± 1.5 3.8 ± 1
Product
profile (12-
HETE:15-
HETE:11-HETE)
100:0:0 73:22:5 100:0:0 29:71a 37:63 a 
Table 1.  Mutagenesis experiments to interrogate binding of the carboxylate end of
fatty acid substrates with hALOX12. Steady state kinetics measurements with AA
and DHA reveal only relatively small differences in the catalytic efficiency between
a more modest reduction in catalytic activity, manifesting a 3.5-fold decrease in 
kcat/KM and a 1.8-fold decrease in kcat, relative to wild-type. These data suggest that 
the side chain aromaticity at position 414 is important for binding, consistent with 
F414 forming a π- π interaction with AA.  
Having established the importance of F414, we investigated which specific 
double bond in AA interacted with F414. The docking model predicted F414 
interacted with either ∆11 or ∆14 so we measured the catalytic rates of mead acid 
(5Z,8Z,11Z-eicosatrienoic acid) with wt-hALOX12 and the two mutant hALOX12s, 
F414L and F414W.  Mead acid has the same 20-carbon length as AA, but only has 
three double bonds, missing the last ∆14 double bond.  It is hypothesized that if 
F414 interacts with the ∆14 double bond, then wt-hALOX12, F414L and F414W 
would all show a decreased activity with mead acid. However, if the interaction 
was with the ∆11 double bond, then the activity of these three LOXs would show the
same pattern as seen with AA. As seen in Table 3, the catalytic activity with mead 
acid follows the same pattern as seen with AA, except that the catalytic efficiency 
actually increases in F414W relative to wt-hALOX12. We therefore conclude that 
the docking model and the AA and mead acid kinetic data are consistent with a 
model in which the aromatic side chain of F414 in hALOX12 π- π stacks with the ∆11-
Enzymes KM  (µM) kcat (s-1) kcat/ KM(µM)-1s-1
       Products (%)
12-
HETE
15-
HETE
wt-
hALOX12 1.9  0.2 28  0.9 14  0.9
100 
5 0
F414L 1.4  0.2    1.7 0.06 1.2  0.1 97  4 3 1
F414W 4.0  0.3 16  0.6 4.0  0.2 100 5 0
Enzymes KM (µM) kcat (s-1) kcat/KM(µM)-1s-1
Products  (%)
12-
HETE
15-
HETE
Wt-
hALOX12 1.3 ± 0.09 1.5 ± 0.03
1.2 ±
0.06
100 
5 0
F414L 1.8 ± 0.5 0.60 ±0.05
0.33 ±
0.07
100 
5 0
F414W 1.9 ± 0.2 8.5 ± 0.2 4.5 ± 0.3 100 5 0
Table 3.  Steady state kinetics and product profile of wt-hALOX12 and its two 414
double bond of AA, similar to that seen for hALOX15. This interaction could 
facilitate the formation of an allyl radical by delocalizing the π-electrons, as 
suggested by earlier studies on hALOX15 and soybean LOX-1.25, 37. It should be 
noted that removal of ∆11 from the substrate eliminates all activity of hALOX12 
since the activated methylene is lost.
Interaction of the fatty acid tail with the hydrophobic bottom of the 
active site.
The importance of the volume of the hydrophobic binding site for the lipid 
tail has been well established as an important factor in determining the 
remarkable specificity of lipoxygenases for fatty acid oxygenation.38 Mutagenesis 
studies on various ALOX15 isoforms led to the development of a hypothesis to 
explain its product specificity,26, 27,39 which postulates that F352, I417, M418 and 
I592 (hALOX15 numbering), which lie at the bottom of the catalytic cavity, regulate
the depth of fatty acid penetration and thus the proper positioning of the substrate
for catalysis.  Similar studies for hALOX12, focusing on A417 and V418 at the 
bottom of the hydrophobic pocket (corresponding to the larger amino acids I417 
and M418 in hALOX15), have been less conclusive. V418M resulted in no 
significant change in positional specificity,28,31 while A417I and the double mutant 
A417M/V418M only altered the positional specificity slightly for hALOX12, with 
~15% of 15-HpETE being produced. In the current work, we observed somewhat 
larger changes in product distribution for the double mutant, A417I/V418M, 
resulting in 24+/- 2% 15-HpETE and a small amount of 11-HpETE (0.5+/- 0.1%), as 
shown in Table 4. Nonetheless, the overall percent change in positional specificity 
of these hALOX12 mutants is lower than that seen for mutations in analogous 
positions for ALOX15s. For example, a single mutation of hALOX15 (I418A) 
increased the yield of 12-HETE from 14% for wt-hALOX15 to 94% for the I418A 
mutant.28 
 We therefore postulated that the hALOX12 active site was wider than that in
hALOX15 and thus could allow for additional space for substrate positioning. The 
residue, S594, was selected for mutation because its corresponding position in 
Enzymes wt-hALOX12 A417I V418M
A417I/
V418M
A417I/
V418M/
S594T
KM  (µM) 1.9 ± 0.2 0.86 ± 0.1 3.2 ± 0.6 0.56 ± 0.1 0.52 ± 0.1
kcat (s-1) 28 ± 0.9 15 ± 0.4 20 ± 2 34 ± 1 2.7 ± 0.09
kcat/KM (µM)-1s-1 14 ± 0.9 18 ± 2 6.3 ± 0.7 59 ± 10 5.1 ± 0.9
Product profile
(12-HETE:15-
HETE:11-
HETE)
100:0:0 85:15:0 100:0:0 75.5:24:0.5 56:46:0
Table 4. Steady state kinetics of mutant enzymes with shallower and narrower cavity.
hALOX15 is occupied by a slightly bulkier residue threonine, which would make the
active site more narrow in hALOX15. We investigated this possibility by creating a 
triple mutant (A417I/V418M/S594T) that makes the base of the cavity not only 
smaller and shallower (A417I and V418M) but also narrower (S594T), as seen in 
Figure 1.  This change results in an increase in 15-HpETE generated to 46+/- 3% 
for A417I/V418M/S594T, as compared to 23+/- 1% for A417I/V418M. 
Considering that A417I/V418M affected the product ratio of AA catalysis, we 
subsequently investigated the effect these mutations would have on fatty acids 
with varied length and unsaturation. The substrates utilized were the C-20 fatty 
acid, 11Z, 14Z-eicosadienoic acid (EDA) and the C-18 fatty acids, 9Z, 12Z-linoleic 
acid (LA) and gamma 6Z, 9Z, 12Z-linolenic acid (GLA). Previous studies in our lab have
shown that EDA and LA are poor substrates for hALOX12 because the bis-allylic 
hydrogen is not positioned properly for hydrogen atom abstraction (Table 5).40 
However, the mutant, A417I/V418M, reacts with both of EDA and LA, effectively 
shifting the substrate backward into the active site so that the bis-allylic carbon, C-
13 for EDA and C-11 for LA, are positioned so the catalytic ferric-hydroxide 
abstracts the proper hydrogen atom. The products generated were as expected, 
100% 15-HpEDA with EDA and 100% 13-HpODE for LA (Table 5). It should be 
noted that GLA is a substrate for wt-hALOX12, but its kcat/KM is very low (kcat/KM = 
0.08 ± 0.01µM-1s-1) and two products are generated, 30+/- 2% 10-HpOTrE and 
70+/- 4% 13-HpOTrE (Table 5). However, the reactivity of GLA with A417I/V418M 
increases 32-fold (Kcat/KM = 2.6 ± 0.10 µM-1s-1) relative to the wt-hALOX12 and it 
produces entirely 13-HpOTrE, as shown in the Table 5. It should be noted that the 
wt-hALOX12 result does not follow the classical interpretation of LOX product 
formation. One would predict that the main product of wt-hALOX12 from GLA 
would be 10-HpOTrE, due to the positioning of C9 near the active site iron, 
however, 13-HpOTrE is the major product. It appears that the shorter length of GLA
relative to AA, not only lowers the catalytic efficiency but also affects substrate 
positioning, by increasing the formation of 13-HpOTrE relative to 10-HpOTrE. For 
all three of these fatty acids, the increase in enzyme activity of the A417I/V418M 
mutant relative to wt-hALOX12 appears to be due to a repositioning of the fatty 
acid by restricting the depth of the active site, such that the bis-allylic hydrogen is 
now positioned properly for abstraction. While this effect is dramatic for these 
three fatty acids since there is little or no activity with wt-hALOX12, it is 
comparable to the change in reactivity wt-hALOX12 and A417I/V418M with AA. 
A417I/V418M produces 24+/- 2% 15-HpETE from AA and given that its kcat/KM is 59 
µM-1s-1, this translates to an approximate kcat/KM of 14 µM-1s-1 for producing 15-
HpETE, which is of comparable magnitude to the kcat/KM values A417I/V418M with 
LA, EDA and GLA.
Critical role of L407 in substrate positioning 
The model of wt-hALOX12 with AA bound suggests that the bulky 
hydrophobic side chain of L407 plays a critical role in defining the “U” shape of the 
binding site and thus properly positioning AA for catalysis. Since L407 is conserved 
in all lipoxygenases25 and is observed at the base of the U-shaped AA in the 
cALOX8 (8R-LOX) co-structure,35 we hypothesized that mutations of L407 would 
affect catalytic efficiency and possibly positional specificity.  Specifically, replacing 
L407 with the much smaller amino acids alanine (L407A) and glycine (L407G) was 
predicted to greatly widen the binding site near the iron, essentially eliminating 
the characteristic “U” shape (Figure 2). Consistent with this hypothesis, we 
observed an ~100–fold decrease in both kcat and kcat/KM for both of these mutants, 
when compared to wt-hALOX12 (Table 6), confirming its important role in 
catalysis. For comparison, we previously mutated this residue in hALOX15 (L407A) 
and demonstrated a 5-fold decrease in kcat and a 3-fold decrease in kcat/KM.41 These 
Fe
Fe
9 12
9 12
Wt-12-LOX
A417I/V418M
Fe
Fe
6 9 12
6 9 12
Wt-12-LOX
A417I/V418M
Fe
Fe
11 14
11 14
Wt-12-LOX
A417I/V418M
Substra
te LA GLA EDA
Enzyme
s
wt-
hALOX12 A417I/ V418M
wt-
hALOX12 A417I/ V418M
wt-
hALOX12 A417I/V418M
KM (µM) NA 2.8 ± 0.5 4.1 ± 0.9 4.7 ± 0.2 NA 1.7 ± 0.6
Kcat (s-1) NA 3.8 ± 0.3 0.34 ±0.03 12 ± 0.3 NA 2.5 ± 0.4
Kcat/KM
(µM)-1s-1 NA 1.4 ± 0.2
0.08 ±
0.01 2.6 ± 0.1 NA 1.4 ± 0.3
Major
Product NA 13-HpODE
13-
HpOTrE 13-HpOTrE NA 15-HpEDA
Table 5.  Steady-state kinetics of the wt-hALOX12 and A417I/V418M mutant enzyme
with linoleic acid (LA), gamma linoleic acid (GLA), and eicosadienoic acid (EDA). The
cartoons in the table are depicting how the double mutant restricts the depth of the
substrate by two carbons. (NA = No activity above the detection limit).
Protein
KM (uM)
(AA)
kcat (s-1)
(AA)
kcat/KM
(uM)-1s-1
     (AA)
Products with AA (%)
12HpET
E
11HpET
E
15HpET
E
Wt-hALOX12 1.9 0.2 28  0.9 14  0.9
100 
5 0 0
L407A 2.4 ±0.2
0.28 ±
0.01
0.12 ±
0.01 91  4 6  1 3  1
L407G 1.8 ±0.3
0.22 ±
0.01
0.12 ±
0.02 60  3 19  2 21  2
L407G/A417I/
V418M
1.5 ±
0.3
0.19 ±
0.01
0.13 ±
0.02 66  3 3  1 31  2
effects are less than that seen for hALOX12, indicating a reduced effect of L407 in 
hALOX15.
In addition, widening the active site cavity with L407A caused a slight 
decrease in positional specificity, with 3+/- 1% 15-HpETE and 6+/- 1% 11-HpETE 
generation. This change in positional specificity increased when the cavity was 
made even larger with the L407G mutant enzyme, with the percentages of the 15-
HpETE and 11-HpETE increasing to 21+/- 2% and 19+/- 2%, respectively (Table 
6). These results imply that L407 is partly responsible for positioning the C10 for 
abstraction,
Figure 2. Relative cavity shapes and sizes of wt-hALOX12, L407A 
with a smaller residue at position 407 possibly leading to a “looser” substrate 
binding mode, thus affecting the percent 15-HpETE product synthesized. The triple 
mutant, L407G/A417I/V418M, increases the percent of 15-HETE even further to 
31+/- 2%, which is consistent with this hypothesis, since A417I/V418M reduce the 
length of the cavity and adjust the substrate positioning further, aligning C13 for 
hydrogen atom abstraction. Previously, the homologous mutation, L546A, in 
soybean LOX-1 was shown to affect catalysis significantly, similar to what we 
observe for L407A.42 Klinman and co-workers determined that the decreased rate 
of L546A was due to an increased cavity size across from the ferric-hydroxide 
moiety, which altered heavy-atom motions and lead to an increase in the energy of
activation for hydrogen atom abstraction. They did not investigate if L546A 
demonstrated altered product reactivity, but given our results it would be a likely 
result. It should be noted that the percentage of 11-HETE increases as the cavity 
increases in size (L407A vs. L407G), but then decreases as the cavity shrinks with 
the triple mutant (L407G/A417I/V418M), suggesting that the 11-HETE product 
correlates with a larger cavity. Finally, we generated the 4 residue mutant, A407G/
A417I/V418M/S594T, to increase the 15-HETE percentage even further, but it was 
inactive, suggesting these four mutations make the enzyme incapable of 
positioning the hydrogen atom for abstraction. We are currently investigating this 
result in more detail to understand the substrate binding determinants in more 
detail.
Substrate positioning in hALOX12 and other lipoxygenases 
The remarkable product specificity achieved by LOX enzymes can be traced 
to proper positioning of substrates in the active site, specifically, (1) how the 
carboxylate group of the fatty acid is anchored as the substrate binds in the active 
site and (2) the depth of the active site.  Here we compare residues that co-
ordinate to the carboxylate group of AA in hALOX12 to other LOX enzymes.  The 
available crystal structure of rALOX15 does not have a substrate or substrate 
analog bound in the active site.  However, a mutational study showed that R402 
from helix 11 in hALOX15 (equivalent to R403 in rALOX15) anchored the 
carboxylate group of AA and LA15.  Structural and mutational studies of cALOX8 
(8R-LOX) showed that R182 from helix 2 hydrogen bonds to the carboxylate 
group of AA.35, 43 The pALOX15 crystal structure showed that Q596 from helix 21 
interacted with the carboxylate group of the co-crystallized substrate-analog 
inhibitor.44  Finally, the results of this study demonstrate that H596 from helix 21 
plays the role of anchoring carboxylate group of AA in hALOX12.   
In Figure 3, we structurally superimpose all of these structures/models, 
highlighting the carboxylate group anchoring residues.  In all cases, the substrate 
binds in a head-to-tail orientation, with the head (i.e., the carboxylate group) 
binding at the entrance of the active site and the hydrophobic tail binding at the 
interior of the protein.  However, the side chains coordinating the carboxylate are 
located on 3 different helices:  helix 11 for rALOX15, helix 21 for pALOX15, and 
helix 2 for cALOX8 (8R-LOX).  These observations, therefore, support the 
hypothesis that LOX enzymes may have evolved to achieve different regio- and 
stereo- specificities by selectively positioning the polar residues on different 
helices near the entrance of active site.
Figure 3.  Superimposed crystal structures of lipoxygenases with differing product 
specificity: cALOX8 (PDB ID 4qwt) co-crystallized with AA (orange), rALOX15 (PDB ID 
2p0m) (cyan), pALOX15 (PDB ID 3rde) co-crystallized with a substrate analog inhibitor 
(green), and AA carbanion-intermediate docked model of hALOX12 from this work 
(magenta).  The side chains of R182 from helix 2 of cALOX8, Q596 from helix 21 of 
pALOX15, H596 from helix 11 of hALOX12, and R403 from helix 11 of rALOX15, which 
co-ordinate with the carboxylate group of the fatty acid, are also shown. Nitrogen, 
oxygen and hydrogen atoms are shown in blue, red and white colors respectively.  
CONCLUSIONS
Human platelet ALOX12 is a critical enzyme in a variety of human biological 
processes and therefore understanding its mechanism of action is highly 
important. In this report, we have performed extensive site-directed mutagenesis 
and molecular modeling to better understand the binding of fatty acids to the 
active site of hALOX12. We observed that the conserved R402 in hALOX12 displays
minimal interactions with the carboxylate end of AA, as opposed to the large 
interaction reported for hALOX15.25 H596 in hALOX12 appears to be better 
positioned to interact with the carboxylic acid, but its effects on hALOX12 catalysis 
are still not as great as that seen for R402 with hALOX15. We also determined that 
F414 in hALOX12 interacts with the ∆11 double bond of AA, similar to that seen in 
hALOX15, indicating a common pi-pi stacking determinant for both hALOX12 and 
hALOX15.25 Our results also demonstrate that A417 and V418 are determinants for 
positional specificity in hALOX12, as observed previously for hALOX15, due to their
defining of the cavity depth.28 In addition, we observe that S594 also contributes to
the positional specificity of hALOX12 by narrowing the cavity and restricting the 
degrees of freedom the methyl tail of AA can sample, thus increasing 15-HETE 
production. Finally, L407 appears to provide a restriction in the active site, which 
constrains the substrate such that the hydrogen from C10 is abstracted with high 
efficiency. These findings are summarized in Figure 4, which highlight the key 
substrate determinants for hALOX12.
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